Comparison of Two Highly Automated ECG Algorithms for Detection of Drug‐Induced Cardiac Ion Channel Block

Figures

• 

  Figure 1. Measured plasma concentration (mean ± 95% CI) for dofetilide, quinidine, ranolazine, and verapamil.

• 

  Figure 2. Comparison of placebo‐adjusted maximal (mean ± 95% CI) changes from baseline in QTcF, J‐Tpeakc, and Tpeak–Tend after dofetilide, quinidine, ranolazine, and verapamil.

• 

  Figure 3. Examples of differences between the FDA and Rhythm Express measurements of T‐wave offset (end of T‐wave). Only annotations of the alternative software are shown. The FDA and alternative interval values are shown below each recording. (a) The differences in the two methods in the presence of a notched T‐wave. (b) The influence of a U‐wave. [Color figure can be viewed at http://wileyonlinelibrary.com]

• 

  Figure 4. Comparison of drug‐induced changes (mean ± 95% CI) for the placebo‐corrected change from baseline from model predictions vs. plasma concentrations using either the FDA or Rhythm Express interval measurements. [Color figure can be viewed at http://wileyonlinelibrary.com]

• 

  Figure 5. Scatterplots of placebo‐adjusted changes from baseline in QTcF, J‐Tpeakc, and Tpeak–Tend measurements from all subjects and timepoints after dofetilide using the FDA and Rhythm Express algorithms. [Color figure can be viewed at http://wileyonlinelibrary.com]

• 

  Figure 6. Scatterplots of placebo‐adjusted changes from baseline in QTcF, J‐Tpeakc, and Tpeak–Tend measurements from all subjects and timepoints after quinidine using the FDA and Rhythm Express algorithms. [Color figure can be viewed at http://wileyonlinelibrary.com]